Impact of N-Acetylcysteine in the mortality of patients hospitalized with COVID-19 : a retrospective cohort study
Copyright © 2023 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved..
INTRODUCTION AND AIM: N-Acetylcysteine has been proposed for the treatment of COVID-19 thanks to its mucolytic, antioxidant and anti-inflammatory effects. Our aim is to evaluate its effect on patients admitted with COVID-19 in mortality terms.
MATERIAL AND METHODS: Retrospective single-center cohort study. All patients admitted to our hospital for COVID-19 from March to April 2020 have been considered.
RESULTS: A total of 378 patients were included, being 196 (51.9%) men, with an average age of 73.3±14.5 years. 52.6% (199) received treatment with N-Acetylcysteine. More than 70% presented coughs, fever, and/or dyspnea. The global hospital mortality was 26.7%. A multivariate analysis through logistic regression identified the age of patients [older than 80; OR: 8.4 (CI95%:3-23.4)], a moderate or severe radiologic affectation measured by the RALE score [OR:7.3 (CI95%:3.2-16.9)], the tobacco consumption [OR:2.8 (CI95%:1.3-6.1)] and previous arrhythmia [OR 2.8 (CI95%: 1.3-6.2)] as risk factor that were independently associated with mortality during the admission. The treatment with N-Acetylcysteine was identified as a protective factor [OR: 0.57 (CI95%: 0.31-0.99)]. Asthma also seems to have a certain protective factor although it was not statistically significant in our study [OR: 0.19 (CI95%: 0.03-1.06)].
CONCLUSIONS: Patients with COVID-19 treated with N-acetylcysteine have presented a lower mortality and a better evolution in this study. Future prospective studies or randomized clinical trials must confirm the impact of N-Acetylcysteine on COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:223 |
|---|---|
| Enthalten in: |
Revista clinica espanola - 223(2023), 8 vom: 15. Okt., Seite 479-485 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galindo-Andúgar, M A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acetylcysteine |
|---|
| Anmerkungen: |
Date Completed 28.09.2023 Date Revised 28.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rceng.2023.07.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359824633 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359824633 | ||
| 003 | DE-627 | ||
| 005 | 20231226081713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rceng.2023.07.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359824633 | ||
| 035 | |a (NLM)37482215 | ||
| 035 | |a (PII)S2254-8874(23)00092-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galindo-Andúgar, M A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of N-Acetylcysteine in the mortality of patients hospitalized with COVID-19 |b a retrospective cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2023 | ||
| 500 | |a Date Revised 28.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved. | ||
| 520 | |a INTRODUCTION AND AIM: N-Acetylcysteine has been proposed for the treatment of COVID-19 thanks to its mucolytic, antioxidant and anti-inflammatory effects. Our aim is to evaluate its effect on patients admitted with COVID-19 in mortality terms | ||
| 520 | |a MATERIAL AND METHODS: Retrospective single-center cohort study. All patients admitted to our hospital for COVID-19 from March to April 2020 have been considered | ||
| 520 | |a RESULTS: A total of 378 patients were included, being 196 (51.9%) men, with an average age of 73.3±14.5 years. 52.6% (199) received treatment with N-Acetylcysteine. More than 70% presented coughs, fever, and/or dyspnea. The global hospital mortality was 26.7%. A multivariate analysis through logistic regression identified the age of patients [older than 80; OR: 8.4 (CI95%:3-23.4)], a moderate or severe radiologic affectation measured by the RALE score [OR:7.3 (CI95%:3.2-16.9)], the tobacco consumption [OR:2.8 (CI95%:1.3-6.1)] and previous arrhythmia [OR 2.8 (CI95%: 1.3-6.2)] as risk factor that were independently associated with mortality during the admission. The treatment with N-Acetylcysteine was identified as a protective factor [OR: 0.57 (CI95%: 0.31-0.99)]. Asthma also seems to have a certain protective factor although it was not statistically significant in our study [OR: 0.19 (CI95%: 0.03-1.06)] | ||
| 520 | |a CONCLUSIONS: Patients with COVID-19 treated with N-acetylcysteine have presented a lower mortality and a better evolution in this study. Future prospective studies or randomized clinical trials must confirm the impact of N-Acetylcysteine on COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hospital mortality | |
| 650 | 4 | |a Mortalidad hospitalaria | |
| 650 | 4 | |a N-Acetilcisteína | |
| 650 | 4 | |a N-Acetylcysteine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Acetylcysteine |2 NLM | |
| 650 | 7 | |a WYQ7N0BPYC |2 NLM | |
| 700 | 1 | |a Arias Arias, Á |e verfasserin |4 aut | |
| 700 | 1 | |a Alfonso García Guerra, J |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Visier, I |e verfasserin |4 aut | |
| 700 | 1 | |a Manuel Fernández Ibáñez, J |e verfasserin |4 aut | |
| 700 | 1 | |a Bellido Maldonado, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista clinica espanola |d 2013 |g 223(2023), 8 vom: 15. Okt., Seite 479-485 |w (DE-627)NLM21591063X |x 2254-8874 |7 nnns |
| 773 | 1 | 8 | |g volume:223 |g year:2023 |g number:8 |g day:15 |g month:10 |g pages:479-485 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rceng.2023.07.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 223 |j 2023 |e 8 |b 15 |c 10 |h 479-485 | ||